72 results about "Genetics predisposition" patented technology

The present invention relates to an in vitro method for diagnosing a genetic predisposition or susceptibility for a cardiovascular disease, condition or disorder in a mammal which comprises detecting of at least three particular single nucleotide polymorphisms (SNP) in a sample obtained from said mammal in at least one of a genomic locus-derived nucleic acid or fragment thereof of the loci APOB, APOE, ABCA1, CETP, LCAT, LIPC, LPL, LDLR, APOC2, APOA5, APOA4, APOC3, and APOA1. Furthermore, the present invention relates to the improved diagnosis that is based on the analysis of several haplotypes for the above-mentioned loci (i.e. a combination of said haplotypes).

Methods are disclosed herein for detecting a genetic predisposition to focal segmental glomerulosclerosis (FSGS) or hypertensive end-stage kidney disease (ESKD) or both in a human subject, e.g., by detecting the presence of at least one single nucleotide polymorphism (SNP) in an APOL1 gene, such as the C-terminal exon of an APOL1 gene. In a further embodiment, methods are disclosed for detecting resistance of a subject to a disease associated with Trypanosoma infection, e.g., by detecting at least one single nucleotide polymorphism (SNP) in an APOL1 gene, such as the C-terminal exon of an APOL1 gene. Also disclosed are methods for treating a subject infected with T. brucei. The methods include administering a therapeutically effective amount of an APOL1 protein including a S342G substitution, an I384M substitution, and / or a deletion of N388 and Y389 to the subject.

A method of predicting the presence of a non-functional BRCA1 gene in a biological sample, comprises the step of assaying the sample for expression of at least one specific member of the S100 family of genes. The invention also describes a kit for predicting the presence of non-functional BRCA1, comprising means for assaying a sample for expression of at least one specific member of the S100 gene family. A method of detecting a genetic predisposition to cancer is also described, comprising the step of assaying a biological sample for expression of a specific member of the S100 family of genes. Also described is a method of determining a suitable chemotherapeutic agent for an individual.

The invention relates to methods for diagnosing a genetic predisposition or susceptibility for anxiety disorders in a human. The methods include detecting particular markers at the human RGS2 locus in a sample obtained from the human. The invention also relates to the improved diagnosis that is based on the analysis of haplotypes for the RGS2 locus.

The invention relates to a precision nutrient meal replacement composition for preventing and treating gestational diabetes and an application method thereof. The precision nutrient meal replacement composition includes a basic preventing and treating bag, a metabolism improvement bag, a micronutrient supplement bag and a hypoglycemic medical and edible bag; the basic preventing and treating bag is composed of soy protein, coarse cereal powder and high oleic peanut oil; the metabolism improvement bag is composed of EPA and DHA; the micronutrient supplement bag is composed of composite mineralsubstances and composite vitamins, wherein the composite mineral substances include Zn, Se and Cr, and the composite vitamins include vitamin C, vitamin B1 and vitamin B2; the hypoglycemic medical andedible bag is composed of inulin, yam powder, tartary buckwheat seeds, lycii fructus, stigma maydis and lotus leaf extract. The application method of the precision nutrient meal replacement composition includes the step of using the basic preventing and treating bag independently or in combination with three other meal replacement bags. The precision nutrient meal replacement composition has theadvantages that different formula combinations are provided for women preparing for pregnancy, pregnant women and postpartum women according to different results of genetic predisposition detection and nutrition assessment, so that the purposes of preventing or treating gestational diabetes are achieved through precise nutrition intervention.

A method and a kit for determining the human with genetic predisposition to increased consumption of carbohydrates and to develop metabolic, psychiatric or neurological disease or disorder, or obesity. The invention pertains to the detection of a human's ADRA2A genotype, and if there is detected the homozygous nucleotide G at the position C-1291 of the ADRA2A gene, then the patient possesses a predisposition to increased consumption of carbohydrates and to develop metabolic, psychiatric or neurological diseases or disorders or obesity, and there is a need to decrease intake of carbohydrates.

The methods of the present invention are based upon the gathering of information from various sources about animals. The information is based upon laboratory testing, genetic analysis and observations by owners and / or trainers about various traits that can be readily observed. Based upon this collection of information, one method generates Performance Index which scores or ranks an animal in terms of how well an animal might function for the intended purpose. Other methods include the ability to selection an optimum breeding pair from one or more stallions and / or one or more mares that would likely produce an offspring with the desired traits.